Recently, ICIs, such as pembrolizumab have been recommended for first‐line treatment in advanced NSCLC patients, whose tumor cell PD‐L1 expression is ≥50% (IHC) and PS (performance status) 0–1. Here, CD274 is linked to non-small cell lung carcinoma.